Renal and Hematologic Toxicity Profile of [177] Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT): A Retrospective Cohort Study.

OBJECTIVE

This study aims to retrospectively evaluate the renal and hematologic toxicity profile of 177Lu-PSMA-RLT in patients with metastatic castration-resistant prostate cancer.

METHODS

Renal function (GFR, BUN, and creatinine) and hematological parameters (hemoglobin, leukocyte, platelet) before and after treatment were examined in 41 patients who received 177Lu-PSMA-RLT at our clinic, and changes along with toxicity grades were determined. Additionally, pre-treatment PSMA PET/CT findings and other demographic and clinical data were assessed.

RESULTS

In terms of renal toxicity, G0-G1 level toxicity was observed in 97.6% of cases, while G2 toxicity was observed in only one patient. This patient already had a low GFR before treatment and experienced only a 2-unit decrease. Regarding hematological toxicity, the rates of G3-4 toxicity were as follows: leukocytes 7.3%, hemoglobin 9.8%, platelets 7.3%.

CONCLUSION

No clinically significant nephrotoxicity was observed with 177Lu-PSMA-RLT. Hematologic toxicity is significant but manageable, and severe side effects are rare and within predictable limits.